Literature DB >> 15741254

Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome.

Deborah P Merke1, Jay N Giedd, Margaret F Keil, Sarah L Mehlinger, E A Wiggs, Stuart Holzer, Erin Rawson, A Catherine Vaituzis, Constantine A Stratakis, George P Chrousos.   

Abstract

Adults with Cushing syndrome frequently develop brain atrophy, memory impairment, and depression, with partial to complete resolution after cure. The effect of excess glucocorticoid exposure on the brain of children has not been systematically studied. Eleven children (six girls, five boys; ages, 8-16 yr) with endogenous Cushing syndrome seen at the National Institutes of Health Clinical Center from 1999-2000 and 10 healthy age- and sex-matched control subjects were studied. Cognitive and psychological evaluations and magnetic resonance imaging of the brain were done before and 1 yr after cure for patients with Cushing syndrome and once for controls. The estimated duration of Cushing syndrome was 4.4 +/- 1.2 yr. When compared with control subjects, children with Cushing syndrome had significantly smaller cerebral volumes (P < 0.001), larger ventricles (P = 0.02), and smaller amygdala (P = 0.004). At baseline, there were no significant differences in IQ between the two groups, and no psychopathology was identified. Despite reversal of cerebral atrophy 1 yr after surgical cure (total cerebral volume, 947 +/- 94 vs.1050 +/- 74 ml, P < 0.001; ventricular volume, 21.4 +/- 12.5 vs. 14.5 +/- 11.6 ml, P < 0.001), children with Cushing syndrome experienced a significant (P < 0.05) decline in Wechsler IQ scores (Full Scale, 112 +/- 19 vs. 98 +/- 14) and a decline in school performance, without any associated psychopathology. The effect of glucocorticoid excess on the brain of children appears to be different from adults. Despite rapid reversibility of cerebral atrophy, children experience a significant decline in cognitive function 1 yr after correction of hypercortisolism.

Entities:  

Mesh:

Year:  2005        PMID: 15741254     DOI: 10.1210/jc.2004-2488

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  45 in total

1.  Computerized Analysis of Brain MRI Parameter Dynamics in Young Patients With Cushing Syndrome-A Case-Control Study.

Authors:  Amit Tirosh; Harish RaviPrakash; Georgios Z Papadakis; Christina Tatsi; Elena Belyavskaya; Lyssikatos Charalampos; Maya B Lodish; Ulas Bagci; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

2.  Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease.

Authors:  Christine Mrakotsky; Peter W Forbes; Jane Holmes Bernstein; Richard J Grand; Athos Bousvaros; Eva Szigethy; Deborah P Waber
Journal:  J Int Neuropsychol Soc       Date:  2012-11-19       Impact factor: 2.892

Review 3.  Cushing's Syndrome in Pediatrics: An Update.

Authors:  Maya B Lodish; Margaret F Keil; Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2018-06       Impact factor: 4.741

4.  Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study.

Authors:  Margaret F Keil; Deborah P Merke; Roma Gandhi; Edythe A Wiggs; Kathy Obunse; Constantine A Stratakis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-17       Impact factor: 3.478

Review 5.  Cushing syndrome in pediatrics.

Authors:  Constantine A Stratakis
Journal:  Endocrinol Metab Clin North Am       Date:  2012-09-27       Impact factor: 4.741

6.  Amygdala volume in patients receiving chronic corticosteroid therapy.

Authors:  E Sherwood Brown; Dixie J Woolston; Alan B Frol
Journal:  Biol Psychiatry       Date:  2007-11-05       Impact factor: 13.382

Review 7.  Psychosomatic aspects of Cushing's syndrome.

Authors:  Nicoletta Sonino; Francesco Fallo; Giovanni A Fava
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

8.  Threat bias in mice with inactivating mutations of Prkar1a.

Authors:  M F Keil; G Briassoulis; M Nesterova; N Miraftab; N Gokarn; T J Wu; C A Stratakis
Journal:  Neuroscience       Date:  2013-03-24       Impact factor: 3.590

9.  Attenuation of amygdala atrophy with lamotrigine in patients receiving corticosteroid therapy.

Authors:  Shuchi Desai; Sadia Khanani; Mujeeb U Shad; E Sherwood Brown
Journal:  J Clin Psychopharmacol       Date:  2009-06       Impact factor: 3.153

10.  Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication.

Authors:  Jonathan Savitz; Allison C Nugent; Wendy Bogers; Alice Liu; Rebecca Sills; David A Luckenbaugh; Earle E Bain; Joseph L Price; Carlos Zarate; Husseini K Manji; Dara M Cannon; Sean Marrett; Dennis S Charney; Wayne C Drevets
Journal:  Neuroimage       Date:  2009-11-17       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.